Published in Parasitol Res on March 25, 2010
Immunization with recombinant leucine aminopeptidase showed protection against Fasciola gigantica in mice. Parasitol Res (2013) 0.81
Inhibition of triclabendazole metabolism in vitro by ketoconazole increases disruption to the tegument of a triclabendazole-resistant isolate of Fasciola hepatica. Parasitol Res (2011) 0.78
Enhancement of the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica using the metabolic inhibitor ketoconazole. Parasitol Res (2010) 0.76
Erratum to: inhibition of triclabendazole metabolism in vitro by ketoconazole increases disruption to the tegument of a triclabendazole-resistant isolate of Fasciola hepatica. Parasitol Res (2011) 0.75
The pharmacokinetics and metabolism of ivermectin in domestic animal species. Vet J (2007) 1.21
Triclabendazole: new skills to unravel an old(ish) enigma. J Helminthol (2005) 1.17
Triclabendazole progress report, 2005-2009: an advancement of learning? J Helminthol (2009) 1.10
Clinical pharmacokinetics and metabolism of benzimidazole anthelmintics in ruminants. Drug Metab Rev (1993) 1.07
The effect of the sulphoxide metabolite of triclabendazole ('Fasinex') on the tegument of mature and immature stages of the liver fluke, Fasciola hepatica. Parasitology (1994) 1.00
The kinetics of triclabendazole disposition in sheep. J Vet Pharmacol Ther (1987) 0.99
Relative activity of triclabendazole metabolites against the liver fluke, Fasciola hepatica. Vet Parasitol (2008) 0.93
Triclabendazole-resistant Fasciola hepatica: beta-tubulin and response to in vitro treatment with triclabendazole. Parasitology (2002) 0.92
A scanning electron microscope study on the route of entry of triclabendazole into the liver fluke, Fasciola hepatica. Parasitology (2009) 0.90
Transmission electron microscope study of the ultrastructural changes induced in the tegument and gut of Fasciola hepatica following in vivo drug treatment with clorsulon. Parasitol Res (2004) 0.90
Altered drug influx/efflux and enhanced metabolic activity in triclabendazole-resistant liver flukes. Parasitology (2005) 0.89
Drug transport mechanisms in helminth parasites: passive diffusion of benzimidazole anthelmintics. Exp Parasitol (2006) 0.88
Fasciola hepatica: tegumental alterations as a consequence of lectin binding. Exp Parasitol (1984) 0.88
Morphological response of triclabendazole-susceptible and triclabendazole-resistant isolates of Fasciola hepatica to treatment in vitro with nitroxynil (Trodax). Parasitol Res (2008) 0.88
The comparative metabolism of triclabendazole sulphoxide by triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica. Parasitol Res (2003) 0.87
Activity of artemether and OZ78 against triclabendazole-resistant Fasciola hepatica. Trans R Soc Trop Med Hyg (2007) 0.87
Response of two isolates of Fasciola hepatica to treatment with triclabendazole in vivo and in vitro. Parasitol Res (2004) 0.86
Fasciola hepatica: surface and internal tegumental changes induced by treatment in vitro with the sulphoxide metabolite of albendazole ('Valbazen'). Parasitology (2003) 0.86
The effect of the hydrogen ionophore closantel upon the pharmacology and ultrastructure of the adult liver fluke Fasciola hepatica. Parasitol Res (1990) 0.86
Assessment of the main metabolism pathways for the flukicidal compound triclabendazole in sheep. J Vet Pharmacol Ther (2006) 0.84
Fasciola hepatica: ultrastructural changes to the tegument of juvenile flukes following incubation in vitro with the deacetylated (amine) metabolite of diamphenethide. Int J Parasitol (1995) 0.84
Fasciola hepatica: morphological effects of a combination of triclabendazole and clorsulon against mature fluke. Parasitol Res (2006) 0.84
Electron microscopical study to assess the in vitro effects of the synthetic trioxolane OZ78 against the liver fluke, Fasciola hepatica. Parasitology (2009) 0.83
Inhibition of cytochrome P450 activity enhances the systemic availability of triclabendazole metabolites in sheep. J Vet Pharmacol Ther (2009) 0.83
Adult triclabendazole-resistant Fasciola hepatica: surface and subsurface tegumental responses to in vitro treatment with the sulphoxide metabolite of the experimental fasciolicide compound alpha. Parasitology (2006) 0.82
Fasciola hepatica: ultrastructural effects of a combination of triclabendazole and clorsulon against mature fluke. Parasitol Res (2006) 0.82
An evaluation of the efficacy of compound alpha and triclabendazole against two isolates of Fasciola hepatica. Vet Parasitol (2009) 0.82
Inhibition of cytochrome P450-mediated metabolism enhances ex vivo susceptibility of Fasciola hepatica to triclabendazole. Parasitology (2009) 0.82
Ultrastructural observations on oral ingestion and trans-tegumental uptake of clorsulon by the liver fluke, Fasciola hepatica. Parasitol Res (2005) 0.82
Fasciola hepatica: tegumental changes induced in vitro by the deacetylated (amine) metabolite of diamphenethide. Exp Parasitol (1986) 0.81
Adult triclabendazole-resistant Fasciola hepatica: morphological changes in the tegument and gut following in vivo treatment with artemether in the rat model. J Helminthol (2009) 0.81
Effect of the metabolic inhibitor, methimazole on the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica. Parasitology (2008) 0.81
Immature triclabendazole-resistant Fasciola hepatica: tegumental responses to in vitro treatment with the sulphoxide metabolite of the experimental fasciolicide compound alpha. Parasitol Res (2006) 0.81
Influence on the antithyroid compound methimazole on the plasma disposition of fenbendazole and oxfendazole in sheep. Res Vet Sci (1995) 0.81
Methimazole increases the plasma concentrations of the albendazole metabolites of netobimin in sheep. Biopharm Drug Dispos (1992) 0.80
Surface and internal tegumental changes in juvenile Fasciola hepatica following treatment in vivo with the experimental fasciolicide, compound alpha. Vet Parasitol (2008) 0.79
Tegumental surface changes in juvenile Fasciola hepatica in response to treatment in vivo with triclabendazole. Vet Parasitol (2008) 0.79
Fasciola hepatica: basal infolds and associated vacuoles of the tegument. Exp Parasitol (1978) 0.79
The interaction between the deacetylated (amine) metabolite of diamphenethide (DAMD) and cytochemically demonstrable Na+/K+-ATPase activity in the tegument of Fasciola hepatica. Parasitol Res (1987) 0.79
Triclabendazole biotransformation and comparative diffusion of the parent drug and its oxidized metabolites into Fasciola hepatica. Xenobiotica (2005) 0.79
A transmission electron microscope study on the route of entry of triclabendazole into the liver fluke, Fasciola hepatica. Parasitology (2009) 0.79
Methimazole-mediated modulation of netobimin biotransformation in sheep: a pharmacokinetic assessment. J Vet Pharmacol Ther (1992) 0.78
Effects of methimazole on the kinetics of netobimin metabolites in cattle. Xenobiotica (1992) 0.77
Ultrastructural changes to the tegumental system and the gastrodermal cells in adult Fasciola hepatica following in vivo treatment with the experimental fasciolicide, compound alpha. Parasitology (2009) 0.77
Ultrastructural changes induced in the tegument and gut of Fasciola hepatica following in vivo and in vitro drug treatment with nitroxynil (Trodax). Parasitol Res (2007) 0.77
Drug resistance in veterinary helminths. Trends Parasitol (2004) 3.04
Does adherence to the guideline recommendation for active treatments improve the quality of care for patients with acute low back pain delivered by physical therapists? Med Care (2007) 1.49
An examination of the reliability of a classification algorithm for subgrouping patients with low back pain. Spine (Phila Pa 1976) (2006) 1.42
Does continuing education improve physical therapists' effectiveness in treating neck pain? A randomized clinical trial. Phys Ther (2008) 1.42
Cathepsin L1, the major protease involved in liver fluke (Fasciola hepatica) virulence: propetide cleavage sites and autoactivation of the zymogen secreted from gastrodermal cells. J Biol Chem (2004) 1.36
The silencing of cysteine proteases in Fasciola hepatica newly excysted juveniles using RNA interference reduces gut penetration. Int J Parasitol (2007) 1.26
Is there a subgroup of patients with low back pain likely to benefit from mechanical traction? Results of a randomized clinical trial and subgrouping analysis. Spine (Phila Pa 1976) (2007) 1.20
Molecular-based reclassification of the bovine enteroviruses. J Gen Virol (2006) 1.10
Drug transfer into target helminth parasites. Trends Parasitol (2007) 1.07
Physical therapy for acute low back pain: associations with subsequent healthcare costs. Spine (Phila Pa 1976) (2008) 1.06
Prolonged exercise to fatigue in humans impairs skeletal muscle Na+-K+-ATPase activity, sarcoplasmic reticulum Ca2+ release, and Ca2+ uptake. J Appl Physiol (1985) (2004) 1.02
Preliminary examination of a proposed treatment-based classification system for patients receiving physical therapy interventions for neck pain. Phys Ther (2007) 0.96
Does the evidence for spinal manipulation translate into better outcomes in routine clinical care for patients with occupational low back pain? A case-control study. Spine J (2006) 0.95
Sex differences in predictors of outcome in selected physical therapy interventions for acute low back pain. J Orthop Sports Phys Ther (2006) 0.94
Multiple origins of European populations of the giant liver fluke Fascioloides magna (Trematoda: Fasciolidae), a liver parasite of ruminants. Int J Parasitol (2010) 0.94
Exercise only, exercise with mechanical traction, or exercise with over-door traction for patients with cervical radiculopathy, with or without consideration of status on a previously described subgrouping rule: a randomized clinical trial. J Orthop Sports Phys Ther (2014) 0.92
Predictive validity of initial fear avoidance beliefs in patients with low back pain receiving physical therapy: is the FABQ a useful screening tool for identifying patients at risk for a poor recovery? Eur Spine J (2007) 0.90
Development and implementation of split-GFP-based bimolecular fluorescence complementation (BiFC) assays in yeast. Biochem Soc Trans (2008) 0.90
A new sensory organ in "primitive" molluscs (Polyplacophora: Lepidopleurida), and its context in the nervous system of chitons. Front Zool (2014) 0.89
A possible model of benzimidazole binding to beta-tubulin disclosed by invoking an inter-domain movement. J Mol Graph Model (2004) 0.88
The Sigma class glutathione transferase from the liver fluke Fasciola hepatica. PLoS Negl Trop Dis (2012) 0.88
Utilization and clinical outcomes of outpatient physical therapy for medicare beneficiaries with musculoskeletal conditions. Phys Ther (2011) 0.88
The comparative metabolism of triclabendazole sulphoxide by triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica. Parasitol Res (2003) 0.87
Activity of artemether and OZ78 against triclabendazole-resistant Fasciola hepatica. Trans R Soc Trop Med Hyg (2007) 0.87
Enhanced dissolution and systemic availability of albendazole formulated as solid dispersions. Pharm Dev Technol (2012) 0.85
Alkalosis increases muscle K+ release, but lowers plasma [K+] and delays fatigue during dynamic forearm exercise. J Physiol (2005) 0.85
Improved albendazole dissolution rate in pluronic 188 solid dispersions. AAPS PharmSciTech (2010) 0.84
Initial management decisions after a new consultation for low back pain: implications of the usage of physical therapy for subsequent health care costs and utilization. Arch Phys Med Rehabil (2013) 0.84
Enantiomeric behaviour of albendazole and fenbendazole sulfoxides in domestic animals: pharmacological implications. Vet J (2009) 0.84
A randomized clinical trial of the effectiveness of mechanical traction for sub-groups of patients with low back pain: study methods and rationale. BMC Musculoskelet Disord (2010) 0.83
Characterisation of two calmodulin-like proteins from the liver fluke, Fasciola hepatica. Biol Chem (2007) 0.82
Comparative proteomic analysis of triclabendazole response in the liver fluke Fasciola hepatica. J Proteome Res (2010) 0.81
Biochemical characterisation of triose phosphate isomerase from the liver fluke Fasciola hepatica. Biochimie (2013) 0.81
FhCaBP3: a Fasciola hepatica calcium binding protein with EF-hand and dynein light chain domains. Biochimie (2012) 0.80
A novel calmodulin-like protein from the liver fluke, Fasciola hepatica. Biochimie (2012) 0.80
Fasciola hepatica expresses multiple alpha- and beta-tubulin isotypes. Mol Biochem Parasitol (2008) 0.80
Effects of faecal residues of moxidectin and doramectin on the activity of arthropods in cattle dung. Ecotoxicol Environ Saf (2008) 0.80
Artemisinins act through at least two targets in a yeast model. FEMS Yeast Res (2010) 0.80
FhCaBP4: a Fasciola hepatica calcium-binding protein with EF-hand and dynein light chain domains. Parasitol Res (2012) 0.80
An amino acid substitution in Fasciola hepatica P-glycoprotein from triclabendazole-resistant and triclabendazole-susceptible populations. Mol Biochem Parasitol (2012) 0.79
Unchanged triclabendazole kinetics after co-administration with ivermectin and methimazole: failure of its therapeutic activity against triclabendazole-resistant liver flukes. BMC Vet Res (2010) 0.79
Detection and localisation of protein-protein interactions in Saccharomyces cerevisiae using a split-GFP method. Fungal Genet Biol (2008) 0.78
Liver fluke β-tubulin isotype 2 binds albendazole and is thus a probable target of this drug. Parasitol Res (2010) 0.77
Vitalizing practice through research and research through practice: the outcomes of a conference to enhance the delivery of care. Phys Ther (2011) 0.77
Fasciola hepatica: disruption of spermatogenesis by the fasciolicide compound alpha. Parasitol Res (2009) 0.77
Milk excretion of ivermectin and moxidectin in dairy sheep: assessment of drug residues during cheese elaboration and ripening period. J Agric Food Chem (2004) 0.77
Differential expression of liver fluke β-tubulin isotypes at selected life cycle stages. Int J Parasitol (2013) 0.77
Placental and fetal toxicity of albendazole sulphoxide in Wistar rats. Vet Hum Toxicol (2003) 0.77
Understanding genetic diversity of the liver fluke Fasciola hepatica. Z Naturforsch C (2005) 0.77
Enhancement of the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica using the metabolic inhibitor ketoconazole. Parasitol Res (2010) 0.76
Plasma and ocular prednisolone disposition after oral treatment in cats. Biomed Res Int (2013) 0.76
Fasciola hepatica: time-dependent disruption of spermatogenesis following in vivo treatment with triclabendazole. Parasitol Res (2011) 0.76
Benzimidazole binding to Haemonchus contortus tubulin: a question of structure. Trends Parasitol (2002) 0.76
Managing physical therapy resources: an analogy to the freedom of the commons and the need for collective action. J Orthop Sports Phys Ther (2012) 0.76
Loperamide modifies the tissue disposition kinetics of ivermectin in rats. J Pharm Pharmacol (2004) 0.76
Echinostoma caproni: differential tegumental responses to growth in compatible and less compatible hosts. Exp Parasitol (2010) 0.76
A plasma membrane Ca(2+)-ATPase (PMCA) from the liver fluke, Fasciola hepatica. Int J Parasitol (2012) 0.76
The effect of the microtubule inhibitor tubulozole-C on the tegument of triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica. Parasitol Res (2003) 0.75
Ultrastructure of head organs (anterior adhesive apparatus) and posterior secretory systems of Caballeria liewi Lim, 1995 (Monogenea, Ancyrocephalidae). Parasitol Res (2014) 0.75
Citrate synthase from the liver fluke Fasciola hepatica. Parasitol Res (2013) 0.75
Binding of serum albumin to the anthelmintic drugs albendazole, triclabendazole and their sulphoxides. Vet Parasitol (2010) 0.75
Mitochondrial DNA haplotype analysis of liver fluke in bison from Bialowieza Primaeval Forest indicates domestic cattle as the likely source of infection. Vet Parasitol (2012) 0.75
The Effectiveness of Mechanical Traction Among Subgroups of Patients With Low Back Pain and Leg Pain: A Randomized Trial. J Orthop Sports Phys Ther (2016) 0.75
Outcomes of Patients With Acute Low Back Pain Stratified by the STarT Back Screening Tool: Secondary Analysis of a Randomized Trial. Phys Ther (2017) 0.75
Disposition of doramectin milk residues in lactating dairy sheep. J Agric Food Chem (2003) 0.75